Sumitomo Pharma America, Inc.
- Country
- 🇺🇸United States
- Ownership
- Subsidiary
- Established
- 1984-01-01
- Employees
- 5K
- Market Cap
- -
- Website
- http://www.sunovion.com
A Multiple Ascending Oral Dose Evaluation of the Safety, Tolerability, and Pharmacokinetics of DSP-1053 and Its Metabolites in Healthy Subjects and in Subjects With Major Depressive Disorder
- First Posted Date
- 2013-01-24
- Last Posted Date
- 2014-06-18
- Lead Sponsor
- Sumitomo Pharma America, Inc.
- Target Recruit Count
- 47
- Registration Number
- NCT01774747
- Locations
- 🇺🇸
California Clinical Trials Medical Group, Glendale, California, United States
Twelve Month Study of the Safety of Eszopiclone in Adult Subjects With Insomnia
- First Posted Date
- 2012-10-19
- Last Posted Date
- 2012-10-22
- Lead Sponsor
- Sumitomo Pharma America, Inc.
- Target Recruit Count
- 791
- Registration Number
- NCT01710631
Adult Attention Deficit Hyperactivity Disorder
- Conditions
- Adult Attention Deficit Hyperactivity Disorder
- Interventions
- Drug: Placebo
- First Posted Date
- 2012-09-25
- Last Posted Date
- 2015-01-12
- Lead Sponsor
- Sumitomo Pharma America, Inc.
- Target Recruit Count
- 341
- Registration Number
- NCT01692782
- Locations
- 🇺🇸
University of California at Irvine, Irvine, California, United States
🇺🇸Collaborative Neuroscience Network Inc, Garden Grove, California, United States
🇺🇸Excell Research, Inc, Oceanside, California, United States
A Study of Daily Dosing With Levalbuterol, Racemic Albuterol, and Placebo in Pediatric Subjects With Asthma
- Conditions
- Asthma
- Interventions
- First Posted Date
- 2012-08-03
- Last Posted Date
- 2012-08-03
- Lead Sponsor
- Sumitomo Pharma America, Inc.
- Target Recruit Count
- 146
- Registration Number
- NCT01656811
A 6 Month Safety Study Of Ciclesonide Nasal Aerosol (Zetonna®) And Ciclesonide Nasal Spray (Omnaris®) In Subjects 12 Years And Older With Perennial Allergic Rhinitis (PAR)
- Conditions
- Perennial Allergic Rhinitis
- Interventions
- First Posted Date
- 2012-07-31
- Last Posted Date
- 2014-07-24
- Lead Sponsor
- Sumitomo Pharma America, Inc.
- Target Recruit Count
- 737
- Registration Number
- NCT01654536
- Locations
- 🇺🇸
Kerrville Research Associates, PA, Kerrville, Texas, United States
🇺🇸Clinical Research Group of Montanta, Bozeman, Montana, United States
🇺🇸Valley Clinical Research Center, Bethlehem, Pennsylvania, United States
Clinical Study of WT2725 in Patients With Advanced Malignancies
- Conditions
- Cancer
- Interventions
- Biological: WT2725
- First Posted Date
- 2012-06-18
- Last Posted Date
- 2019-07-17
- Lead Sponsor
- Sumitomo Pharma America, Inc.
- Target Recruit Count
- 64
- Registration Number
- NCT01621542
- Locations
- 🇺🇸
The University of Chicago Medical Center, Chicago, Illinois, United States
🇺🇸The University of Texas MD Anderson Cancer Center, Houston, Texas, United States
🇺🇸The University of Texas, MD Anderson Cancer Center, Houston, Texas, United States
Lurasidone Pediatric Pharmacokinetics Study
- First Posted Date
- 2012-06-15
- Last Posted Date
- 2016-04-08
- Lead Sponsor
- Sumitomo Pharma America, Inc.
- Target Recruit Count
- 105
- Registration Number
- NCT01620060
- Locations
- 🇺🇸
Atlanta Center for Medical Research, Atlanta, Georgia, United States
🇺🇸Woodland International Research Group, Inc., Little Rock, Arkansas, United States
🇺🇸Woodland Northwest Research, LLC, Springdale, Arkansas, United States
This is an Open-label, Multi-center, Extension Study Designed to Evaluate the Longer Term Safety, Tolerability and Effectiveness of Lurasidone, Flexibly Dosed, Adjunctive to Lithium or Divalproex for the Treatment of Subjects With Bipolar I Disorder Who Have Participated in Study D1050296
- First Posted Date
- 2012-04-11
- Last Posted Date
- 2016-08-22
- Lead Sponsor
- Sumitomo Pharma America, Inc.
- Target Recruit Count
- 377
- Registration Number
- NCT01575561
- Locations
- 🇺🇸
Atlanta Center for Medical Research, Atlanta, Georgia, United States
🇺🇸Psychoneuroendocrinology Research Group, Dept of Psychiatry, UT Southwestern Medical Center, Dallas, Texas, United States
🇵🇱NZOZ BioMed, Kielce, Poland
A Twelve Week, Open Label Extension Study in Patients With Schizophrenia
- First Posted Date
- 2012-03-29
- Last Posted Date
- 2019-04-09
- Lead Sponsor
- Sumitomo Pharma America, Inc.
- Target Recruit Count
- 191
- Registration Number
- NCT01566162
- Locations
- 🇺🇸
AXIS Clinical Trials, Los Angeles, California, United States
🇺🇸CNRI-Los Angeles. LLC, Pico Rivera, California, United States
🇺🇸Neuropsychiatric Research Center of Orange County, Santa Ana, California, United States
A Phase 1, Open-Label, Single-photon Emission Computed Tomography (SPECT) Study to Evaluate Serotonin and Dopamine Transporter Occupancy After Multiple Dose Administration of SEP-228432 to Achieve Steady State in Healthy Subjects
- First Posted Date
- 2012-02-13
- Last Posted Date
- 2013-12-09
- Lead Sponsor
- Sumitomo Pharma America, Inc.
- Target Recruit Count
- 30
- Registration Number
- NCT01531972
- Locations
- 🇺🇸
Molecular NeuroImaging, New Haven, Connecticut, United States